Ulcerative Colitis Market Forecast 2036: Growing Adoption of Targeted Therapies and Strong Pipeline to Drive Market Expansion - DelveInsight

DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive analysis of ulcerative colitis, covering historical and forecasted epidemiology along with market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Get a Free sample for the Ulcerative Colitis Market Report:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Some of the key facts of the Ulcerative Colitis Market Report:

• The Ulcerative Colitis market in the 7MM was valued at approximately USD 9.4 billion in 2025 and is projected to reach nearly USD 21.0 billion by 2036, growing at a CAGR of 7.6% during the forecast period (2025-2036).
• In 2025, the United States accounted for approximately USD 6.6 billion of the total ulcerative colitis market, supported by the increasing adoption of advanced targeted therapies.
• The treatment landscape has expanded with the approval of TREMFYA (guselkumab) by Johnson & Johnson, SKYRIZI (risankizumab) by AbbVie, VELSIPITY (etrasimod) by Pfizer, and OMVOH (mirikizumab) by Eli Lilly, reflecting the shift toward targeted biologics and oral therapies.
• In April 2026, Abivax announced that nine scientific abstracts on obefazimod would be presented during Digestive Disease Week (DDW) 2026, highlighting Phase III efficacy, safety, patient-reported outcomes, and preclinical anti-fibrotic activity.
• In February 2026, Phase III data presented at ECCO 2026 demonstrated that obefazimod produced rapid improvements in patient-reported symptoms while maintaining a safety profile comparable to placebo.
• In November 2025, Abivax reported positive patient-reported outcomes from the Phase III ABTECT induction trials, showing significant quality-of-life improvements among patients with moderate-to-severe ulcerative colitis.
• In July 2025, Abivax announced positive Phase III results from both ABTECT 8-week induction studies evaluating its oral miR-124 enhancer obefazimod in moderate-to-severe ulcerative colitis.
• Emerging therapies such as obefazimod (ABX464), tulisokibart (MK-7240), olamkicept, Afimkibart (RVT-3101), and MORF-057 are expected to further diversify treatment options during the forecast period.
• The market continues to evolve with increasing physician preference for IL-23 inhibitors, JAK inhibitors, S1P receptor modulators, and other targeted immune therapies, offering improved remission rates and steroid-sparing benefits.
• According to DelveInsight estimates, nearly 3.3 million diagnosed prevalent cases of ulcerative colitis were reported across the 7MM in 2025.
• The United States accounted for approximately 1.6 million diagnosed prevalent cases in 2025.
• Among EU4 countries, Germany recorded the highest number of diagnosed moderate-to-severe ulcerative colitis cases, while Italy reported the lowest.
• In Japan, approximately 222,400 moderate-to-severe diagnosed prevalent cases of ulcerative colitis were estimated in 2025.
• Current treatment includes 5-aminosalicylic acids, corticosteroids, immunomodulators, biologics, and oral targeted therapies, while several innovative therapies continue advancing through late-stage clinical development.
• Key Ulcerative Colitis Companies include Johnson & Johnson, AbbVie, Pfizer, Eli Lilly, Abivax, Merck, Ferring Pharmaceuticals, Morphic, Roche, Roivant, Prometheus Biosciences, and others.
• Key Ulcerative Colitis Therapies include TREMFYA (guselkumab), SKYRIZI (risankizumab), VELSIPITY (etrasimod), OMVOH (mirikizumab), Obefazimod (ABX464), Tulisokibart (MK-7240), Olamkicept, and others.
• The Ulcerative Colitis market is expected to expand considerably during the forecast period owing to the growing disease burden, wider use of advanced biologics and oral targeted therapies, and the anticipated launch of several pipeline candidates with novel mechanisms of action.

Ulcerative Colitis Overview

Ulcerative colitis is a chronic inflammatory bowel disease characterized by persistent inflammation and ulceration of the inner lining of the colon . The disease typically begins in the may extend continuously throughout part or all of the colon. Common symptoms include diarrhea, rectal bleeding, abdominal pain, urgency to defecate, fatigue, and weight loss. Although its exact cause remains unknown, ulcerative colitis is believed to result from genetic susceptibility, immune dysfunction, environmental triggers, and alterations in the gut microbiome. Treatment focuses on reducing inflammation, inducing remission, maintaining long-term disease control, and preventing relapse through conventional therapies, biologics, oral targeted agents, and surgery in severe cases.

To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerative Colitis Market Forecast-
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Ulcerative Colitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends of ulcerative colitis across the seven major markets (7MM) from 2022 to 2036. It analyzes the diagnosed patient population, disease burden, and future epidemiological trends while incorporating findings from published studies and expert opinions to better understand the factors influencing disease prevalence and diagnosis.

Ulcerative Colitis Epidemiology Segmentation:

• Total Diagnosed Prevalent Cases of Ulcerative Colitis
• Age-specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Severity-specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Total Treated Cases of Ulcerative Colitis

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ Ulcerative Colitis Epidemiology Forecast-
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities

The drug uptake section evaluates the expected adoption of currently marketed and upcoming therapies during the forecast period. The analysis examines therapy uptake, patient utilization patterns, market share, and projected sales performance of individual treatments.

The therapeutics assessment also highlights therapies expected to achieve rapid clinical adoption based on efficacy, safety, route of administration, physician preference, and competitive positioning. In addition, the report compares leading products based on their anticipated market share across the 7MM.

The report further provides a comprehensive overview of Ulcerative Colitis pipeline development activities, profiling promising candidates across different stages of clinical development. It also reviews recent regulatory milestones, collaborations, licensing agreements, acquisitions, mergers, patents, and other strategic developments shaping the future treatment landscape.

Ulcerative Colitis Therapies and Key Companies

• TREMFYA (guselkumab): Johnson & Johnson
• SKYRIZI (risankizumab): AbbVie
• VELSIPITY (etrasimod): Pfizer
• OMVOH (mirikizumab): Eli Lilly
• Obefazimod (ABX464): Abivax
• Tulisokibart (MK-7240): Merck
• Olamkicept: Ferring Pharmaceuticals
• MORF-057: Morphic
• Afimkibart (RVT-3101): Roivant
• Additional pipeline therapies from Roche, Prometheus Biosciences, and other companies

Discover more about therapies set to grab major Ulcerative Colitis market share @ Ulcerative Colitis Treatment Market-
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Ulcerative Colitis Market Drivers

• Rising prevalence and increasing disease burden of ulcerative colitis worldwide.
• Continuous advancements in biologics and targeted therapies improving treatment outcomes.
• Growing adoption of oral small-molecule therapies, including JAK inhibitors and S1P receptor modulators.
• Increasing physician focus on long-term remission, mucosal healing, and steroid-sparing treatment strategies.
• Robust late-stage clinical pipeline introducing innovative mechanisms of action to address unmet clinical needs.

Ulcerative Colitis Market Barriers

• Limited long-term effectiveness of existing biologic therapies in a subset of patients.
• Treatment resistance and loss of response requiring frequent therapy switching.
• Safety concerns associated with prolonged corticosteroid and immunosuppressant use.
• High treatment costs that may affect patient access and reimbursement.
• Persistent unmet need for therapies offering durable remission, improved safety, and long-term disease control.

Scope of the Ulcerative Colitis Market Report

• Study Period: 2022-2036
• Coverage: 7MM
• Key Ulcerative Colitis Companies: Johnson & Johnson, AbbVie, Pfizer, Eli Lilly, Abivax, Merck, Ferring Pharmaceuticals, Morphic, Roche, Roivant, Prometheus Biosciences, and others.
• Key Ulcerative Colitis Therapies: TREMFYA (guselkumab), SKYRIZI (risankizumab), VELSIPITY (etrasimod), OMVOH (mirikizumab), Obefazimod (ABX464), Tulisokibart (MK-7240), Olamkicept, and others.
• Ulcerative Colitis Therapeutic Assessment: Current marketed therapies and emerging pipeline therapies.
• Ulcerative Colitis Market Dynamics: Market drivers and market barriers.
• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, reimbursement analysis, competitive landscape assessment, and market opportunity evaluation.
• Ulcerative Colitis Unmet Needs, KOL Views, Analyst Perspectives, and Market Access & Reimbursement Analysis.

Table of Contents

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Ulcerative Colitis Market Overview at a Glance
7. Disease Background and Overview of Ulcerative Colitis
8. Epidemiology and Patient Population of Ulcerative Colitis
9. Patient Journey of Ulcerative Colitis
10. Marketed Therapies
11. Emerging Drugs
12. Ulcerative Colitis: 7MM Analysis
13. Unmet Needs of Ulcerative Colitis
14. SWOT Analysis of Ulcerative Colitis
15. KOL Views of Ulcerative Colitis
16. Market Access and Reimbursement of Ulcerative Colitis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.